Registration is officially OPEN for the 2024 DTRF Together We Will Weekend and RFA Walk. - Register Now

The Desmoid Tumor Research Foundation

November 2017

Safety and efficacy of intralesional steroid injection for aggressive fibromatosis

Author Information

Pruksakorn D(1)(2), Lorsomradee S(3), Phanphaisarn A(4), Teeyakasem P(4), Klangjorhor J(4), Chaiyawat P(4), Kosachunhanun N(5), Settakorn J(6), Arpornchayanon O(7)

(1)Orthopedic Laboratory and Research Network (OLARN), Department of Orthopedics Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.(2)Excellence Center in Osteology Research and Training Center (ORTC), Chiang Mai University, Chiang Mai, Thailand.(3)Department of Anesthesiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.(4)Orthopedic Laboratory and Research Network (OLARN), Department of Orthopedics Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.(5)Endocrinology Unit, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.(6)Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.(7)Bangkok Hospital Chiang Mai, Chiang Mai, Thailand.

Publication

World J Surg Oncol

Summary

Treatment of recurrent aggressive fibromatosis (AF) following surgical resection is a clinical challenge. Non-steroidal anti-inflammatory drugs(NSAIDs) have been reported to be an effective option for controlling the disease. However, long-term NSAID use can result in unfavorable complications. This study was a trial of the use of intralesional steroid injection (ILSI) including investigation of safety margins and clinical outcomes of high-dose steroids for local use treatment of AF. A prospective cohort study was conducted to evaluate the safety and efficacy of particulate corticosteroids for AF. Intralesional steroid injections of Kanolone(R) guided by ultrasound were given monthly for three consecutive months with 1 mg/kg/episode (a total of 3 mg/kg). Eight recurrent AF patients completed the full 6-month evaluation process. The highest number of complication events, all of which were mild or detectable only by laboratory analysis, occurred during the month following the second injection. Tumors were stabilized in 83.3% of the cases during the study period, and pain and functional ability scores improved significantly. Intralesional steroid injection appears to be a safe and effective alternative treatment for recurrent AF.

View Abstract